Akamis Bio | Evaluate

A bad day for Molecular Partners

Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.

September 23, 2019

As the heat rises, Clovis turns to radionuclides

The beleaguered drug maker has licensed a preclinical FAP-directed radiopharmaceutical, a target that has made little progress.

September 13, 2018

Another must-have oncolytic virus asset for big pharma

Boehringer Ingelheim struck a deal with the oncolytic virus company Viratherapeutics in 2016, and it has clearly seen something extraordinary in the intervening two…

February 21, 2018

Merck & Co makes biggest oncolytic virus bet since Amgen in 2011

June 02, 2017

Sachs Forum – Deciphering the immunology combo avalanche

December 23, 2016

Snippet roundup: Biogen's chief exec choice underwhelms as a big 2016 decision is delayed to 2017

December 13, 2016

Setbacks fail to stifle oncolytic virus business development

February 04, 2016

Imperial marches against the tide with big funding round

August 18, 2015

Therapeutic focus – Cachexia research enlivened by cancer asset chase

April 30, 2015

Adcom puts T-Vec on track to underwhelm

September 03, 2013

Therapeutic focus – Big pharma adds weight to thin cachexia pipeline

Load More